Abstracts Archive - Page 1713 of 2607 - ACR Meeting Abstracts

Abstract Number: 1707 • 2016 ACR/ARHP Annual Meeting
Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Fenglong Xie¹, Lang Chen¹, Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody, is a relatively new biologic used for the treatment of psoriasis (PSO) and psoriatic arthritis (PSA). Its…
Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting
Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis
Julia Manasson¹, Soumya M. Reddy¹, Andrea L. Neimann², Leopoldo N. Segal³ and Jose U. Scher¹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Dermatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 1710 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Symptoms Preceding the Diagnosis of Psoriatic Arthritis – a Qualitative Exploration of the Patient Journey
Nigara Rasappu¹, Kim Wervers², Ilja Tchetverikov³, Marc R. Kok⁴, Andreas H. Gerards⁵, Marijn Vis¹ and Jolanda J. Luime¹, ¹Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Vlietland Hospital, Schiedam, Netherlands
Background/Purpose: Given the difficulties non-rheumatologists experience to early refer psoriasis patients at risk for Psoriatic Arthritis (PsA) we aim to explore patients experience of musculoskeletal…
Abstract Number: 1711 • 2016 ACR/ARHP Annual Meeting
Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Juan J. Gomez-Reino³, Jürgen Wollenhaupt⁴, Maurizio Cutolo⁵, Georg Schett⁶, Eric Lespessailles⁷, Melissa McIlraith⁸, ChiaChi Hu⁸, Christopher J. Edwards⁹, Charles A. Birbara¹⁰ and Philip J Mease¹¹, ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁵University of Genova, Genova, Italy, ⁶University of Erlangen-Nuremberg, Erlangen, Germany, ⁷University of Orléans, Orléans, France, ⁸Celgene Corporation, Summit, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA, ¹¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Of the multiple manifestations of psoriatic arthritis (PsA), enthesitis and dactylitis are hallmark features that affect many patients (pts), can lead to pain and…
Abstract Number: 1712 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Physical Functioning and Work for People with Psoriatic Arthritis: Results from a Large Real-World Study in 16 Countries
Philip G. Conaghan¹, Rieke Alten², Vibeke Strand³, Atul A. Deodhar⁴, Emma Sullivan⁵, Stuart Blackburn⁵, Haijun Tian⁶, Kunal Gandhi⁶ and Steffen Jugl⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Division of Immunology/Rheumatology, Stanford University, California, CA, ⁴Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Adelphi Real World, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: <3); employment status and the four WPAI components (work time missed, impairment while working, overall work impairment, and activity impairment) were described by HAQ-DI…
Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Philip J Mease¹, Dafna D Gladman², Juan J Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Kamal Shah⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orléans, Orléans, France, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 1716 • 2016 ACR/ARHP Annual Meeting
Higher Frequency and Severity of Coronary Plaques on Coronary CT Angiography in Psoriatic Arthritis Patients without Symptoms of Coronary Artery Disease Compared to Controls
Agnes Szentpetery¹, Darragh Brady², Gerard Healy², Ciaran Redmond², Hannah Fleming², John Duignan², Muhammad Haroon¹, Jonathan Dodd² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Radiology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Patients with psoriasis (PsO) and psoriatic arthritis (PsA) have an increased prevalence of cardiovascular (CV) risk factors, metabolic syndrome (Metsy), and higher risk…
Abstract Number: 1717 • 2016 ACR/ARHP Annual Meeting
Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Alba Quesada-Moreno¹, Maria Dolores Sanchez-González², Laura Pérez-Garrido³, Ricardo Usategui-Martín⁴, Guadalupe Manzano-Canabal¹, Cristina Hidalgo-Calleja¹, Olga Martínez-González¹, Javier Del Pino-Montes¹ and Carlos Alberto Montilla-Morales¹, ¹Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ²HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ³Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ⁴IBSAL, SALAMANCA, Spain
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of…
Abstract Number: 1718 • 2016 ACR/ARHP Annual Meeting
Ustekinumab, Apremilast, TNFi and the Risk for Hospitalized Infection in Patients with Psoriasis and Psoriatic Arthritis
Fenglong Xie¹, Lang Chen¹, Huifeng Yun², Timothy Beukelman³ and Jeffrey Curtis⁴, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ³Pediatric Rheumatology, University of Alabama-Birmingham, Birmingham, AL, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody and apremilast, an inhibitor of phosphodiesterase 4 are two relatively new agents used for the treatment of…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 1720 • 2016 ACR/ARHP Annual Meeting
Predictive Value of Different Tools for Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, GR Burmester⁴, Siegfried Wassenberg⁵, Benjamin Köhler⁶, Ulrich Kaesser⁷, Marina Backhaus⁸, Harald Burkhardt⁹ and Frank Behrens⁹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumazentrum, Ratingen, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷6Internistische Praxisgemeinschaft am Krankenhaus Balserische Stiftung Gießen, Gießen, Germany, ⁸Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin disease in Europe. Psoriatic arthritis (PsA) is closely associated to Pso; the skin…
Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Augusta Ortolan¹, Giovanni Boschetti², Mariagrazia Lorenzin¹, Giulia Cherobin³, Leonardo Punzi³, Massimo Puato² and Roberta Ramonda³, ¹Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ²Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].